Lexaria Bioscience Corp. (NASDAQ: LEXX) announced today that it has extended its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original agreement, entered into on August 30, 2024, was designed to evaluate Lexaria's DehydraTECH™ technology in a pre-clinical setting. The extension accommodates the time needed for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1 therapies.
Under the extended MTA, the temporary exclusive license remains active, allowing the two parties to continue their collaborative relationship. The extension also opens the door for additional strategic planning discussions involving PharmaCO's human clinical and business development teams. This development underscores the potential of Lexaria's drug delivery platform in the rapidly growing GLP-1 market, which includes treatments for diabetes and obesity.
Over the past 12 months, Lexaria has made significant progress in its GLP-1 development program. The company has announced advancements in three key 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria's technology. These studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of 2026.
The DehydraTECH platform is Lexaria's patented drug delivery formulation and processing technology that improves oral drug delivery. It has demonstrated the ability to increase bio-absorption, reduce side effects, and enhance drug delivery across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio, including 65 granted patents and additional patents pending worldwide. For more information, visit Lexaria Bioscience.
The extension of the MTA is a positive signal for Lexaria, as it indicates continued interest from a pharmaceutical partner in the company's technology. It also provides Lexaria with additional time to generate compelling data from its ongoing studies, which could lead to broader licensing agreements or collaborations. The GLP-1 drug class has seen explosive growth, with products like Ozempic and Wegovy generating billions in sales. Lexaria's technology could potentially improve the oral bioavailability of these drugs, offering a competitive advantage.
Forward-looking statements in this release involve risks and uncertainties, including those related to research outcomes, regulatory approvals, and market conditions. The company disclaims any obligation to update these statements. For more details, refer to Lexaria's filings with the U.S. Securities and Exchange Commission.
